IL2 and Miyoshi myopathy: However, a phase II clinical trial of zoledronate/IL-2 treated MM patients after BM transplantation led to only 18% of complete remission (CR) due to a progressive reduction of γδ T cells in vivo expansion despite several cycles of zoledronate/IL-2 injections (60).